SMMT ▼ -6.0% - Summit Therapeutics Inc.
FDA rejected
$SMMT
ivonescimab. No survival benefit in mEGFR lung cancer, no approval. Adam F on X
15-NOV-2026 09:05 AM ET
Share this post
More filings for $SMMT
SMMT ▼ -6.0% - Summit Therapeutics Inc.Nov 15, 2026SMMT ▲ +2.3% - Summit Therapeutics Inc.Nov 4, 2026SMMT ▼ -1.1% - Summit Therapeutics Inc.Nov 4, 2026SMMT ▲ +0.3% - Summit Therapeutics Inc.Oct 23, 2026SMMT ▼ -3.9% - Summit Therapeutics Inc.Oct 22, 2026SMMT ▲ +0.6% - Summit Therapeutics Inc.Oct 21, 2026
View full $SMMT filing history →💬 Comments
Loading comments…
Leave a comment